JPRN-UMIN000030938招募中2 期
A phase II study of Nivolumab re-challenge therapy after VEGF inhibitor therapy in patients with advanced non-small cell lung cancer. Gunma-Ibaraki-Fukushima-Tochigi (GIFT) group study - Nivolumab re-challenge therapy after VEGF inhibitor therapy.
GIFT group0 个研究点目标入组 25 人开始时间: 2018年1月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Symptomatic brain metastasis 2)Active infections diseases 3)Serious complications 4)Active concomitant cancers 5)Severe adverse events of Nivolumab 6)Pregnancy, breastfeeding or suspected of being pregnant 7)Those judged to be not suitable by the attending physician
研究者
相似试验
已完成
2 期
A phase 2 trial of Nivolumab in recurrent or metastatic platinum-refractory non-squamous cell carcinoma of the head and necknon-squamous cell carcinoma of the head and neckJPRN-UMIN000029636Medical Oncology / Hematology, Department of Medicine Kobe University Hospital and Graduate School of Medicine24
进行中（未招募）
1 期
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon CancerEUCTR2013-003939-30-BEBristol-Myers Squibb International Corporation375
进行中（未招募）
1 期
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon CancerMSI Positive Colorectal CancerMSI Negative Colorectal CancerMedDRA version: 21.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003939-30-IEBristol-Myers Squibb International Corporation375
进行中（未招募）
2 期
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarkerJPRN-jRCTs031180013Kagamu Hiroshi60
已完成
不适用
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarkernon-small-cell lung cancerJPRN-UMIN000028468orst East Japan Study Group(NEJSG)60